lactosporin

Sabinsa Corporation, a vertically integrated, research-oriented company known for providing sustainable natural, well researched ingredients for hair and skin care formulations, will be exhibiting at the annual New York Chapter of Society of Cosmetic Chemists event, also known as Suppliers’ Day. This year, NYSCC Suppliers’ Day, which primarily focuses on innovative ingredients and cosmetic formulations, will be held on May 03-04, 2022, at Jacob K. Javits Convention Center, New York City.

Sabinsa Expands UK and EU Footprint with New Staff

Sabinsa has opened two new satellite offices in the UK and in Spain to support customers in Europe. The Spanish office will service Spain, Portugal, the Iberian Peninsula, Southern France, and Northwestern Africa. The UK office will support customers in the UK and Ireland in navigating changes and challenges brought about by Brexit.

Sabinsa Cosmeceutical Ingredients COSMOS Approved

Sabinsa’s intellectual property portfolio now includes 308 separate patents granted across the world. The most recent patents granted include several from Australia, Canada, Europe, and the USA. Sabinsa’s patent portfolio includes composition, use and process patents. Many are for various aspects of category leader ingredients such as LactoSpore®, DigeZyme® and Curcumin C3 Complex®; others are for relatively new, up and coming ingredients such as Nigellin® and Sabroxy®.

Sabinsa as a Sanction For Discovery Abuses in Litigation

Sami-Sabinsa Group Limited, the world leader in Curcumin for the dietary supplements industry, has been awarded more than $1 Million in attorney’s fees and costs against Prakruti Products. The award, issued by a federal judge in New Jersey on May 24, came in the wake of Sabinsa’s successful prosecution of Prakruti’s egregious discovery misconduct. The Magistrate Judge had previously imposed non-monetary sanctions on Prakruti, and that ruling was affirmed by the District Judge on appeal. The award is Sabinsa’s latest win in a years-long discovery battle with Prakruti that began in June 2017, after the Court reopened a settled case involving Prakruti’s infringement of Sami-Sabinsa’s patented Curcumin C3 Complex®.